AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17270317
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (7.2 g/day for 14 days)
Trial: 17270317
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (7.2 g/day for 14 days) in fasting conditions
Trial: 11231986
Drug: L-thyroxine [64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine [64 nmol.day(‐)(1) (0.05 mg.day(‐)(1))]
Trial: 11231986
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (L-thyroxine and placebo)
Trial: 23520976
Drug: Granisetron (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (1 mg/mL, 0.5 mL)
Trial: 23520976
Drug: Control (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isotonic saline, 9 mg/mL, 0.5 mL)
Trial: 20535948
Drug: Bevacizumab (antiangiogenesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (antiangiogenesis therapy)
Trial: 20535948
Drug: Small molecules
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Small molecules of VEGF-TKI
Trial: 8267489
Drug: Anti-factor Xa
RxNorm normalized name: Innohep, 20,000 anti-Factor Xa intl units/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-factor Xa monitoring (targeted range, 0.35 to 0.67 U/mL)
Trial: 3114564
Drug: Histamine (0.06‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (0.06‐2 micrograms in 0.1 ml saline)
Trial: 3114564
Drug: Terfenadine (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (20, 40, 60, and 120 mg, p.o.)
Trial: 20627451
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity behavioral treatment (average 6.5h per week)
Trial: 16409338
Drug: IMPACT service
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPACT service (Inpatient Management of acute Pain and Advice on Clinical Treatment)
Trial: 10987602
Drug: Azimilide 100
RxNorm normalized name: Azimilide
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide 100 mg and 125 mg
Trial: 10987602
Drug: Azimilide 50
RxNorm normalized name: Azimilide
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide 50 mg
Trial: 14967728
Drug: Azimilide 100
RxNorm normalized name: Azimilide
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide 100 mg
Trial: 3085131
Drug: Mecamylamine (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (2.5, 5.0, 10, 20 mg)
Trial: 26701793
Drug: MFGM (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFGM (10 g Lacprodan PL-20, twice daily)
Trial: 26701793
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 g Miprodan 30, twice daily)
Trial: 12182742
Drug: Omeprazole triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole triple therapy
Trial: 7669310
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with alfentanil (0.5 mcg/kg initial dose, continuous infusion 0.2 to 0.5 mcg/kg/min, self-administered 3 to 5 mcg/kg with a 5-minute lockout)
Trial: 7669310
Drug: Physician-controlled analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-controlled analgesia with continuous infusions (0.75 mcg/kg/min) and intermittent boluses (5 mcg/kg) of alfentanil
Trial: 1836062
Drug: Fish diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish diet (0.15 g EPA/d, 0.41 g DHA/d)
Trial: 1836062
Drug: Fish +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish + Oil diet (0.99 g EPA/d, 0.99 g DHA/d)
Trial: 1836062
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil alone (5 g/d for 6 weeks, 0.84 g EPA/d, 0.48 g DHA/d)
Trial: 31603245
Drug: 3-month strict
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month strict oral hygiene phase
Trial: 31603245
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no instructions or motivation on oral hygiene)
Trial: 7994666
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 240 mg (oral administration)
Trial: 2563744
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 8.8 mg azelastine
Trial: 197446
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (15 to 60 mg, subcutaneously administered)
Trial: 31565898
Drug: NA-XY (nalbuphine-xylazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA-XY (nalbuphine-xylazine combination: xylazine 1.1mL/100 kg IV and nalbuphine 1 mg/kg IV)
Trial: 29164254
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin (7.5 mg/d)
Trial: 23314000
Drug: Routine Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Family Therapy (RFT)
Trial: 23644823
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) - up to 1500 mg iron
Trial: 12826316
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus cisplatin (GP) - gemcitabine 1200 mg/m² on days 1 and 8 plus cisplatin 80 mg/m² on day 2.
Trial: 12826316
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus carboplatin (GC) - gemcitabine 1200 mg/m² on days 1 and 8 plus carboplatin AUC=5 on day 2.
Trial: 9124195
Drug: Gallium nitrate
RxNorm normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallium nitrate 200 mg/m2/day and hydroxyurea 500 mg/day
Trial: 9124195
Drug: Gallium nitrate
RxNorm normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallium nitrate 250 mg/m2/day and hydroxyurea 1,000 mg/day
Trial: 9124195
Drug: Gallium nitrate
RxNorm normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallium nitrate 300 mg/m2/day and hydroxyurea 1,000 mg/day
Trial: 9124195
Drug: Gallium nitrate
RxNorm normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallium nitrate 350 mg/m2/day and hydroxyurea 1,000 mg/day
Trial: 9124195
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of gallium nitrate and hydroxyurea
Trial: 2940475
Drug: Transdihydrolisuride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdihydrolisuride (1 mg daily)
Trial: 8964274
Drug: Felbamate monotherapy
RxNorm normalized name: Felbamate
DrugBank: Felbamate (DB00949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felbamate monotherapy
Trial: 6614410
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg cimetidine orally 120 to 180 minutes prior to induction of anaesthesia
Trial: 6614410
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg cimetidine rectally in small children up to 15 kg
Trial: 21157170
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no moxibustion treatment)
Trial: 16386621
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir for the first 21 days
Trial: 16386621
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir followed by oral ganciclovir up to day 120 posttransplantation (historical control group)
Trial: 10348929
Drug: Highly selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly selective inhibitors of cyclooxygenase-2 (COX-2)
Trial: 2279802
Drug: Ibuprofen (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (7 mg/kg)
Trial: 2279802
Drug: Paracetamol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (8 mg/kg)
Trial: 7247696
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg i.v. infusion)
Trial: 7247696
Drug: Placebo (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equal volume and infusion speed)
Trial: 31491873
Drug: Phytosterol emulsion
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol emulsion (1.5 g/day phytosterol equivalents)
Trial: 22326642
Drug: HBV-ISS (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV-ISS (2 doses at 0 and 4 weeks)
Trial: 22326642
Drug: HBV-Eng (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV-Eng (3 doses at 0, 4, and 24 weeks)
Trial: 19497643
Drug: Educational magazine
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational magazine (twice monthly)
Trial: 8064171
Drug: Garlic preparation
RxNorm normalized name: garlic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic preparation (Kwai)
Trial: 3120557
Drug: Terfenadine associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine associated with cytoprotective drugs (pirenzepine or rosaprostol)
Trial: 3120557
Drug: Terfenadine associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine associated with anti-H2 receptor antagonists (ranitidine or famotidine)
Trial: 18349597
Drug: Mesotherapy (mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesotherapy (mixed solution of aminophylline, buflomedil, and lidocaine) injected weekly into the superficial dermis of one thigh for 12 weeks.
Trial: 18349597
Drug: Mesotherapy (mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesotherapy (mixed solution of aminophylline, buflomedil, and lidocaine)
Trial: 12506176
Drug: Concurrent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent bolus cisplatin with radiation (arm B)
Trial: 12506176
Drug: Split course
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split course of radiation with concurrent infusional fluorouracil and bolus cisplatin (arm C)
Trial: 12506176
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily fractionated radiation (arm A, control)
Trial: 2203397
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin during streptokinase infusion (group 1)
Trial: 2203397
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin after streptokinase infusion (group 2)
Trial: 31531771
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Streptococcus dentisani (n=5)
Trial: 31531771
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of Streptococcus dentisani for a week (n=6)
Trial: 31531771
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing schedules of Streptococcus dentisani
Trial: 28093815
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (NSO) 500 mg twice daily for 4 weeks
Trial: 21285160
Drug: SCIO-469 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCIO-469 30 mg IR
Trial: 21285160
Drug: SCIO-469 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCIO-469 60 mg IR
Trial: 21285160
Drug: SCIO-469 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCIO-469 100 mg ER
Trial: 14736573
Drug: Nicotine administered
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine administered by patch (3.5 mg for low-hostility non-smokers, 21 mg for high-hostility smokers)
Trial: 14736573
Drug: Nicotine administered
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine administered by patch (21 mg)
Trial: 9771059
Drug: Prednisolone pre-treatment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone pre-treatment
Trial: 23860964
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cells (MSCs) at a dose of 2 × 10(6) cells/kg for each infusion twice a week for 4 weeks, with the option for weekly infusions for an additional 4 weeks if needed.
Trial: 21771568
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg every 21-28 days)
Trial: 19155070
Drug: Adherence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence therapy (8 sessions)
Trial: 9593789
Drug: Daily chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily chlorambucil
Trial: 9593789
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group for first trial)
Trial: 9593789
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group for second trial)
Trial: 3058874
Drug: 12-week regimen
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week regimen of adjuvant chemotherapy
Trial: 3058874
Drug: 36-week regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36-week regimen of adjuvant chemotherapy
Trial: 29308522
Drug: Ibuprofen 300mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 300mg, bid for 5 days after scaling and root planing (SRP)
Trial: 26094712
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (nurse titrated analgesia)
Trial: 23035844
Drug: AC952 Aloe
RxNorm normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC952 Aloe vera inner leaf gel powder
Trial: 23035844
Drug: UP780 Aloe
RxNorm normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP780 Aloe vera inner leaf gel powder standardized with 2% aloesin
Trial: 20707253
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg plus codeine 60 mg tid for 24 hours (Group A)
Trial: 20707253
Drug: Ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 10 mg qid for 24 hours (Group B)
Trial: 16488952
Drug: DS-MMC (deep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-MMC (deep sclerectomy with intraoperative low dose mitomycin C 0.25 mg/ml for 2 minutes)
Trial: 15106284
Drug: Sodium enoxaparin
RxNorm normalized name: Enoxaparin Sodium
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium enoxaparin administered for 10 days
Trial: 15106284
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy (corticosteroids, vasoactive agents, multivitamins, and anticoagulants)
Trial: 11102254
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg bolus followed by 75 mg per day for 3-12 months) + Aspirin
Trial: 11102254
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Ticlopidine
Trial: 4062333
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide injection
Trial: 4062333
Drug: Topical 0.05%
RxNorm normalized name: ingenol topical 0.05% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.05% betamethasone dipropionate under occlusion
Trial: 20149955
Drug: 12-month group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month group behavioral treatment designed to increase autonomy and self-regulation for weight control
Trial: 14671145
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist starting on day 1 of stimulation (n = 30)
Trial: 14671145
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist starting on day 6 of stimulation (n = 30)
Trial: 8636452
Drug: Chlorhexidine diacetate
RxNorm normalized name: Chlorhexidine diacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine diacetate gum (20 mg total daily)
Trial: 8636452
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gluconate mouthwash (40 mg total daily)
Trial: 30643069
Drug: Manipulation combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulation combined with biofeedback electrical stimulation treatment for 30 days
Trial: 30643069
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation biofeedback therapy
Trial: 24972190
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg tid for a mean of 36.6 days
Trial: 19416227
Drug: Fluticasone 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 0.005% ointment
Trial: 17634259
Drug: CHO+PRO (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO+PRO (0.3 g x kg(‐1) protein hydrolysate)
Trial: 17634259
Drug: CHO (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (0.3 g x kg(‐1) carbohydrate)
Trial: 11437018
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group treatment for depression
Trial: 9510453
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of CPAP
Trial: 28095544
Drug: Same-day sequential
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day sequential Q-switched Nd:YAG laser and 1565 nm non-ablative fractional laser (SST)
Trial: 28095544
Drug: Fractional non-ablative
RxNorm normalized name: OMIDUBICEL NON-CULTURED FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional non-ablative laser (NAFL) treatment only
Trial: 19392908
Drug: Extended Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended Cognitive Behavioral Therapy (E-CBT)
Trial: 19392908
Drug: Extended Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended Nicotine Replacement Therapy (E-NRT)
Trial: 12737857
Drug: Rectal adenoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal adenoma
Trial: 11876893
Drug: Irradiated drug-containing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiated drug-containing porcine-cornea (ofloxacin, acetyl cysteine, reduced glutathione)
Trial: 9292758
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (six mugs daily)
Trial: 6367413
Drug: verapamil (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil (0.2 mg/kg total by bolus and by 10-minute infusion)
Trial: 27367585
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with 10 mg Lutein, 2 mg Zeaxanthin, and 10 mg Meso-zeaxanthin for 12 months
Trial: 24440210
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of Ty21a vaccine with anti-helminthic treatment
Trial: 24440210
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of Ty21a vaccine without anti-helminthic treatment
Trial: 14996676
Drug: Peginterferon-alpha2a, 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon-alpha2a, 180 microg/wk for 48 weeks plus standard-dose ribavirin (1000 or 1200 mg/d)
Trial: 14996676
Drug: Peginterferon-alpha2a, 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon-alpha2a, 180 microg/wk for 24 weeks plus low-dose ribavirin (800 mg/d)
Trial: 14996676
Drug: Peginterferon-alpha2a, 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon-alpha2a, 180 microg/wk for 48 weeks plus low-dose ribavirin (800 mg/d)
Trial: 14996676
Drug: Peginterferon-alpha2a, 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon-alpha2a, 180 microg/wk for 24 weeks plus standard-dose ribavirin (1000 or 1200 mg/d)